New osteoporosis drug awaiting approval in UK and US
A new drug to treat osteoporosis is waiting for approval in both the UK and US. The drug Prolia would be injected 2x/year and is considerably less expensive than its bisphosphonate competition currently on the market like Fosamax and Boniva.
The new drug could provide an option for women who cannot tolerate Fosamax like drugs. Currently, one in four women cannot tolerate Fosamax like medications because of serious Fosamax side effects, such as digestive problems.
In the UK, the new drug, (generic- denosumab), is licensed, but is still being assessed for NHS use by the National Institute for Health and Clinical Excellence.
Subscribe to:
Post Comments (Atom)
Fosamax In The News
Posts
0 comments:
Post a Comment